Mylan launches chronic hepatitis B treatment tabs

mylan on teva Mylan has serious concerns about Teva’s ability to integrate and efficiently run a combined company, and deliver meaningful shareholder value, he said, adding “there is simply no track record for investors to find”. (Reuters)

The tablet has been launched in the strength of 25 mg

Drug firm Mylan Pharmaceuticals has launched tenofovir alafenamide tablets under the brand name ‘HepBest’, used for treatment of chronic hepatitis B in adults, in India. HepBest is the first drug in eight years to be approved for the management of chronic hepatitis B in India, Mylan Pharmaceuticals said in a statement. The tablet has been launched in the strength of 25 mg, it added.

Commenting on the development, Rakesh Bamzai, President, Mylan India and Emerging Markets said, “Mylan continues to be in the forefront of introducing new treatment regimens for the management of hepatitis in India.” By bringing the best-in-class drug for hepatitis B management, HepBest, to India, Mylan hopes to provide care for chronic hepatitis B patients and improve overall management of the disease, he added.